minimed

Type 2 Diabetes deserves better.

Clinical evidence for MiniMed™ 780G System in Patients with Type 2 Diabetes on MDI

International guidelines explicitly recommend AID for type 2 diabetes on MDI.[1]

Automated insulin delivery should be offered for diabetes management to youth and adults on MDI with type 2 diabetes.

	Baseline HbA1c > 8.0%		Overall	
	Run-in (N=38)	Study (N=35)	Run-in (N=95)	Study (N=91)
TDD, U	81.2 ± 38.8	105.3 ± 58.0	77.4 ± 38.5	91.8 ± 49.3
Total basal, U	46.4 ± 20.5	57.5 ± 30.7	46.0 ± 21.9	50.1 ± 26.6
Total bolus, U	34.8 ± 25.0	47.8 ± 35.7	31.4 ± 25.1	41.7 ± 28.8
Auto correction, %TB	--	34.2 ± 19.7	--	34.4 ± 22.5



Figure 1. Glycaemia and insulin delivery during the run-in and study periods. HbA1c, continuous glucose monitoring derived metrics, and insulin delivery for the overall group and stratified by baseline HbA1c >8.0%. AHCL, advanced hybrid closed loop; HbA1c, glycosylated hemoglobin.

†N=88, ‡N=34

Clinically significant improvements in HbA1C, %TIR and %TAR.[2]

No increase in hypoglycaemia,
No significant change
in weight or BMI.[2]

7.2% HBA1c at 3 months.[2]

63% No prior pump or CGM experience.[2]

Don’t wait to intensify.

Therapeutic inertia remains one of the greatest barriers to optimal outcomes in type 2 diabetes.[1]

	Self reported T2D			
	All Settings		≥ 100 IU	
	All users (N=10,795)	TDD ≤ 100 IU (N=7,961)	TDD ≥ 100 IU (N=2,834)	Using recommended settings (N=868)
GMI, %	7.0 ± 0.5	6.9 ± 0.5	7.1 ± 0.5	7.2 ± 0.7†
Recommended setting use, %	26.5	25	30.6	--
Mean SG, mmol/L	8.5 ± 1.3	8.4 ± 2.0	8.8 ± 1.4	--

Figure 2. Glycaemia outcomes of real world MiniMed™ 780G system users with self-reported T2D with or without a TDD of >100 IU. (TDD) Total Daily Dose of Insulin; (IU) Insulin Units; (T2D) Type 2 Diabetes.[3]

~65-70%

of insulin, was delivered automatically by the system.[3]

Not just a trial result.

Findings hold up across 26,427 real world users.[3]

Now indicated for adults with insulin-requiring type 2 diabetes.

Ask about our monthly plans, including sensors and consumables for system use.

MiniMed™ 780G System^

^Components sold separately.

†Users need to bolus on the system. The study showed user-initiated boluses (something participants were doing in their prior therapy) decreased.[2]

Please refer to the product insert or Instructions for Use for a complete list of indications, contraindications, warnings, precautions, and other important medical information.

For further information, contact your local MiniMed™ representative.

References 1. American Diabetes Association Professional Practice Committee, et al. Diabetes Care. 2026;49(Suppl 1):S150–S165. 2. Bhargava A, et al. Diabetes Technol Ther. 2025;27(5):366–375. 3. Thijs I, et al. J Diabetes Sci Technol. 2025:19322968251318373.
Please refer to the product insert or Instructions for Use for a complete list of indications, contraindications, warnings, precautions, and other important medical information. For further information, contact your local MiniMed™ representative.

Medtronic Australasia Pty Ltd. Level 8, 11 Khartoum Road, Macquarie Park, NSW 2113 Australia. Tel: +61 2 9857 9000, Toll Free: 1800 777 808. Email: australia.diabetes@medtronic.com. Approval AU-DBA-2600010.

minimed